Long-term study of adults with Ph+ ALL who relapsed or didn't respond
Part of Blood & lymphatic, Cancer clinical trials.
This trial follows adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that has come back or hasn't gotten better with treatment. It aims to understand how people do over time and what factors affect their health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a specific type of leukemia called Ph+ ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia).
- Your leukemia has come back (relapsed) or hasn't responded to previous treatment (refractory).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how to treat a type of leukemia called Ph-negative ALL in adults. It may help people by testing a treatment approach specifically for this leukemia subtype.
This study follows adults with Philadelphia chromosome-positive ALL who are receiving a combination of targeted therapy (a BCR::ABL1 inhibitor) and other treatments. It collects real-world data to better understand how these treatments work.
This study follows how well a “pediatric-style” treatment plan works in teens and young adults with Ph-negative acute lymphoblastic leukemia (ALL) in real-world care. It mainly aims to understand outcomes and safety for patients who fit the specific leukemia and health criteria.
This trial tests a new treatment plan for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). It aims to see if the combination of drugs can effectively control the leukemia while keeping side effects manageable.
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
This trial tests a treatment plan for adults aged 18 to 65 who have just been diagnosed with a type of acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome (Ph-negative). The goal is to see how well this therapy works and how safe it is.
Hear when a new Ph Positive ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.